Shingrix vaccine market set for rapid growth, report says

The Business Research Company says the global Shingrix (Zostavax) market is poised for strong expansion through 2035, driven by rising shingles awareness, aging populations and wider adult immunization programs. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The Shingrix (Zostavax) market supports prevention of shingles in older adults, a population at higher risk of complications. - Market growth could help reduce cases of post-herpetic neuralgia, one of the most common and painful shingles complications. - Higher vaccine uptake also points to broader preventive-care spending and stronger adult immunization coverage.

What happened: - The Business Research Company released its Global Shingrix (Zostavax) Market Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report says the market is entering a period of rapid growth. - The report places North America as the largest regional market in 2025. - The report identifies Asia-Pacific as the fastest-growing region going forward. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Historical growth was driven by greater awareness of shingles complications, a growing older population and limits associated with live attenuated vaccines. - Expanded immunization guidance for older adults also supported demand. - Physician recommendations helped increase vaccine use. - Future growth is expected to come from higher adult vaccination targets, more spending on preventive services, a growing pipeline of recombinant vaccines and government-backed immunization programs. - Vaccination adoption is a major growth driver because vaccines train the immune system to recognize and fight disease. - Public health campaigns, stronger healthcare infrastructure and global vaccination efforts have helped raise vaccination rates. - Shingrix offers protection against shingles and related complications for adults aged 50 and above. - A May 2024 Journal of the American Medical Association study reported a 46% increase in shingles vaccinations covered by Medicare Part D in the year after the IRA policy took effect in January 2023. - The report includes new 2026 features such as market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The report points to a market shift from awareness-led growth to policy- and infrastructure-led growth. - Medicare-related uptake data suggests reimbursement and public policy are becoming more important to vaccine demand. - The focus on recombinant vaccines signals a broader move away from older vaccine constraints.

What's next: - Adult immunization programs are likely to remain a key demand driver as governments and health systems push higher coverage. - Preventive-care spending and vaccination policy changes may continue to shape regional growth patterns. - Asia-Pacific's expansion will likely track healthcare investment and broader access to adult vaccines. - The company is offering a free sample and full report through its website.